Skip to main content
SpringerLink
Log in

Rituximab and ofatumumab safe in children with nephrotic syndrome

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Bonanni A, et al. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. British Journal of Clinical Pharmacology : 13 Feb 2018. Available from: URL: http://doi.org/10.1111/bcp.13548

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rituximab and ofatumumab safe in children with nephrotic syndrome. Reactions Weekly 1691, 10 (2018). https://doi.org/10.1007/s40278-018-42265-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-42265-0

Search

Navigation